Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Download these expert-selected slides on treating patients with AML without targetable biomarkers.
Daniel Pollyea, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 2.07 MB
Released: December 13, 2021

Acknowledgements

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Genentech, a member of the Roche Group

Related Content

Downloadable slides on managing adverse events associated with asparaginase-based therapy in patients with ALL, from Clinical Care Options (CCO)

Emily Curran, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors in relapsed/refractory CLL/SLL, from Clinical Care Options (CCO).

Jeff Sharman, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors for the frontline treatment of CLL/SLL from Clinical Care Options (CCO).

Susan M. O'Brien, MD Released: December 9, 2022

Downloadable slideset from Dr. Eytan M. Stein on selecting therapy for AML patients with predictive biomarkers or actionable alterations, from Clinical Care Options (CCO)

Eytan M. Stein, MD Released: December 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings